UB Paderborn / Katalog / Suche / in CDI

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

World journal of gastroenterology : WJG, 2014-08, Vol.20 (31), p.10984-10993

2014

Volltextzugriff (PDF)

Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo‐controlled study

Alimentary pharmacology & therapeutics, 2013-04, Vol.37 (7), p.680-690

2013

Volltextzugriff (PDF)

Colonic ornithine decarboxylase in inflammatory bowel disease : Ileorectal activity gradient, guanosine triphosphate stimulation, and association with epithelial regeneration but not the degree of inflammation and clinical features

Digestive diseases and sciences, 2007, Vol.52 (1), p.25-30

2007

Volltextzugriff (PDF)

Efficacy of Chronic Hepatitis C Therapy in Community-Based Trials

Clinical gastroenterology and hepatology, 2009-10, Vol.7 (10), p.1028-1036

2009

Volltextzugriff (PDF)

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Journal of hepatology, 2015-06, Vol.62 (6), p.1246-1255

2015

Volltextzugriff (PDF)

Chronic hepatitis C： Treat or wait？ Medical decision making in clinical practice

World journal of gastroenterology : WJG, 2012-03, Vol.18 (12), p.1339-1347

Claus Niederau Dietrich Huppe EImar Zehnter Bernd Moiler, Renate Heyne Stefan Christensen Rainer Waft Arno Theilmeier Ulrich Alshuth Stefan Mauss

2012

Volltextzugriff (PDF)

Sa1034 Sustained Responders After Antiviral Treatment of Chronic Hepatitis C Have a Better Quality of Life and Productivity Independent of Genotype, Age and Opioid Maintenance

Gastroenterology (New York, N.Y. 1943), 2013-05, Vol.144 (5), p.S-978-S-978

2013

Volltextzugriff (PDF)

Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-975-S-976

2014

Volltextzugriff (PDF)

Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-977-S-977

2014

Volltextzugriff (PDF)

240 Similar Adjusted Svr12 Rates for HIV Co-Infected and HCV Mono-Infected Patients and No Dose or Population (Treatment-Naïve/Relapser) Effect: Pooled Analysis of Faldaprevir Phase III Trials

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-905-S-905

2014

Volltextzugriff (PDF)

Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial: 487

The American journal of gastroenterology, 2013-10, Vol.108, p.S145

2013

Volltextzugriff (PDF)

Sa1053 Age-Dependent Rise in Early Hemoglobin (HB) Decline Contributes to a Higher Frequency of Anemia in Elder Patients Treated With Peginterferon Alfa-2B (Peg2b)/Ribavirin (RBV) for Chronic HCV Genotype 1 (G1) Infection

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-956-S-956

2012

Volltextzugriff (PDF)

Sa1052 Thyroid Dysfunction Triggered by Peginterferon Alfa-2B / Ribavirin Treatment of Chronic HCV Genotype 1 Infection Favors Sustained Virologic Response (SVR) by Reducing

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-956-S-956

2012

Volltextzugriff (PDF)

Sa1072 Early Markers of Metabolic Syndrome are Associated With Distinct HCV Genotypes, While Abnormal Glucose Tolerance Substantially Decreases the Likelihood of SVR

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-961-S-961

2012

Volltextzugriff (PDF)

M1797 Evaluation of a Predictive Model of Individual Chance for Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-840-A-840

2009

Volltextzugriff (PDF)

Dose Reduction of Peginterferon Alfa-2a (PEG) in Combination With Ribavirin (RBV) in Chronic Hepatitis C (CHC) Patients: Impact on Virological Response Under Real Life Conditions

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-948-S-948

2011

Volltextzugriff (PDF)

Pathological Glucose Levels and Presence of Hypertension Identifies HCV Patients With Minor Treatment Responses

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-933-S-933

2011

Volltextzugriff (PDF)

Treatment of Naive Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA: e108751

PloS one, 2014-10, Vol.9 (10)

2014

Volltextzugriff (PDF)

M1791 Role of Rvr and Viral Load On SVR in Treatment of GT3 Hepatitis C Patients with Peginterferon Alfa-2a (PEG) and Ribavirin (RBV) in Real Life

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-839-A-839

2009

Volltextzugriff (PDF)

M1794 Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) (PEG) and Ribavirin (RBV) in Genotype 5 and 6 Patients with Chronic Hepatitis C Under Real Life Conditions

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-839-A-840

2009

Volltextzugriff (PDF)

W1004 Sustained Virologic Response and Relapse Rates with Peginterferon Alfa-2b Plus Ribavirin in Clinical Trials Are Comparable to Those in Community-Based Studies

Gastroenterology (New York, N.Y. 1943), 2008, Vol.134 (4), p.A-830-A-830

2008

Volltextzugriff (PDF)

W1001 The Role of Cholesterol On Sustained Virological Response (SVR) in the Treatment of Genotype-1 Infected Hepatitis C (cHC) Patients with Peginterferon Alfa-2a (PEG) and Ribavirin (RBV)

Gastroenterology (New York, N.Y. 1943), 2008, Vol.134 (4), p.A-829-A-829

2008

Volltextzugriff (PDF)

W1010 Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) and Ribavirin in Genotype 4 Patients with Chronic Hepatitis C (cHC) Under Real Life Conditions

Gastroenterology (New York, N.Y. 1943), 2008, Vol.134 (4), p.A-831-A-831

2008

Volltextzugriff (PDF)

Colleague references on chronic diarrhea: an array of diagnoses (interview by Dr. med. Thomas Meissner)

MMW Fortschritte der Medizin, 2003-10, Vol.145 (43), p.12

2003

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA

Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo‐controlled study

Colonic ornithine decarboxylase in inflammatory bowel disease : Ileorectal activity gradient, guanosine triphosphate stimulation, and association with epithelial regeneration but not the degree of inflammation and clinical features

Efficacy of Chronic Hepatitis C Therapy in Community-Based Trials

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Chronic hepatitis C： Treat or wait？ Medical decision making in clinical practice

Sa1034 Sustained Responders After Antiviral Treatment of Chronic Hepatitis C Have a Better Quality of Life and Productivity Independent of Genotype, Age and Opioid Maintenance

Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction

Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies

240 Similar Adjusted Svr12 Rates for HIV Co-Infected and HCV Mono-Infected Patients and No Dose or Population (Treatment-Naïve/Relapser) Effect: Pooled Analysis of Faldaprevir Phase III Trials

Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial: 487

Sa1053 Age-Dependent Rise in Early Hemoglobin (HB) Decline Contributes to a Higher Frequency of Anemia in Elder Patients Treated With Peginterferon Alfa-2B (Peg2b)/Ribavirin (RBV) for Chronic HCV Genotype 1 (G1) Infection

Sa1052 Thyroid Dysfunction Triggered by Peginterferon Alfa-2B / Ribavirin Treatment of Chronic HCV Genotype 1 Infection Favors Sustained Virologic Response (SVR) by Reducing

Sa1072 Early Markers of Metabolic Syndrome are Associated With Distinct HCV Genotypes, While Abnormal Glucose Tolerance Substantially Decreases the Likelihood of SVR

M1797 Evaluation of a Predictive Model of Individual Chance for Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin

Dose Reduction of Peginterferon Alfa-2a (PEG) in Combination With Ribavirin (RBV) in Chronic Hepatitis C (CHC) Patients: Impact on Virological Response Under Real Life Conditions

Pathological Glucose Levels and Presence of Hypertension Identifies HCV Patients With Minor Treatment Responses

Treatment of Naive Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA: e108751

M1791 Role of Rvr and Viral Load On SVR in Treatment of GT3 Hepatitis C Patients with Peginterferon Alfa-2a (PEG) and Ribavirin (RBV) in Real Life

M1794 Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) (PEG) and Ribavirin (RBV) in Genotype 5 and 6 Patients with Chronic Hepatitis C Under Real Life Conditions

W1004 Sustained Virologic Response and Relapse Rates with Peginterferon Alfa-2b Plus Ribavirin in Clinical Trials Are Comparable to Those in Community-Based Studies

W1001 The Role of Cholesterol On Sustained Virological Response (SVR) in the Treatment of Genotype-1 Infected Hepatitis C (cHC) Patients with Peginterferon Alfa-2a (PEG) and Ribavirin (RBV)

W1010 Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) and Ribavirin in Genotype 4 Patients with Chronic Hepatitis C (cHC) Under Real Life Conditions

Colleague references on chronic diarrhea: an array of diagnoses (interview by Dr. med. Thomas Meissner)

Suchergebnisse filtern